AllianceBernstein
ETON icon

AllianceBernstein’s Eton Pharmaceutcials ETON Stock Holding History

AllianceBernstein’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,600
Closed -$209K – 3253
2025
Q3 		$209K Buy
+9,600
New +$159K ﹤0.01% 3067

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

AllianceBernstein's ETON Position: Q4 2025 in Review

AllianceBernstein sold out of Eton Pharmaceutcials (ETON) in Q4 2025, closing a stake of 9,600 shares — an estimated $209K sold.

AllianceBernstein first reported a position in ETON in Q3 2025 and held it in 1 quarter. The position peaked at $209K in Q3 2025. 104 funds tracked by Wall St. Rank hold ETON as of Q4 2025.

  • AllianceBernstein reported no remaining Eton Pharmaceutcials position as of Q4 2025 after selling out during the quarter.
  • AllianceBernstein sold 9,600 Eton Pharmaceutcials shares in Q4 2025, an estimated $209K.
  • AllianceBernstein first reported a position in Eton Pharmaceutcials in Q3 2025 and held it in 1 quarter.
  • AllianceBernstein's Eton Pharmaceutcials position peaked at $209K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q4 2025.

Based on AllianceBernstein's 13F filing for Q4 2025, filed 17 Feb 2026.